WP
QNCX icon

Westmount Partners’s Quince Therapeutics QNCX Stock Holding History

Westmount Partners’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-50
Closed -$10.6K – 223
2024
Q1 		$10.6K Sell
50
-1
-2% -$248 ﹤0.01% 212
2023
Q4 		$10.7K Hold
51
– – ﹤0.01% 201
2023
Q3 		$11.4K Hold
51
– – 0.01% 192
2023
Q2 		$15.3K Hold
51
– – 0.01% 186
2023
Q1 		$15.8K Hold
51
– – 0.01% 183
2022
Q4 		$6.47K Buy
+51
New +$8.53K ﹤0.01% 172

Other funds holding QNCX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Westmount Partners's QNCX Position: Q2 2024 in Review

Westmount Partners sold out of Quince Therapeutics (QNCX) in Q2 2024, closing a stake of 50 shares — an estimated $10.6K sold.

Westmount Partners first reported a position in QNCX in Q4 2022 and held it in 6 quarters. The position peaked at $15.8K in Q1 2023. 41 funds tracked by Wall St. Rank hold QNCX as of Q2 2024.

  • Westmount Partners reported no remaining Quince Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Westmount Partners sold 50 Quince Therapeutics shares in Q2 2024, an estimated $10.6K.
  • Westmount Partners first reported a position in Quince Therapeutics in Q4 2022 and held it in 6 quarters.
  • Westmount Partners's Quince Therapeutics position peaked at $15.8K in Q1 2023.
  • 41 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2024.

Based on Westmount Partners's 13F filing for Q2 2024, filed 28 Jan 2025.